Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 10OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastric Adenocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 5Capecitabine 3toripalimab 2olaparib 2durvalumab 2darolutamide 2atezolizumab 2apatinib 2anlotinib 2Standard of Care 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Laparoscopy 2Immunotherapy 2Fluorouracil 2Drug Therapy 2130-nm albumin-bound paclitaxel 2trametinib 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1hetrombopag 1glasdegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × apatinib × 90 days × Clear all
NCT07618546 2026-06-01

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Henan Cancer Hospital

Phase NA Not yet recruiting
208 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07610629 2026-05-28

RA-A-NP

Henan Cancer Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡